en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

Research Update: Studies Support CyberKnife for Neurological Disease Treatment

Two studies recently presented at the annual meeting of the European Association of Neurosurgical Societies (EANS) reinforced the benefits of stereotactic radiosurgery for neurological diseases, using the CyberKnife® system.

In a study completed at the University Hospital of Messina in Italy, Dr. Alfredo Conti used CyberKnife technology to treat perioptic meningioma, a type of benign tumor that arises from the membranes that surround the brain and spinal cord. The noninvasive treatment approach preserved vision while maintaining tumor control within 64 patients treated in 2-5 treatment sessions.

A second study evaluated the benefits of the CyberKnife system to treat patients with trigeminal neuralgia, a nerve disorder characterized by chronic facial pain. The study, led by Prof. Pantaleo Romanelli, analyzed the treatment of 103 patients. After six months, more than 90 percent of patients showed significant improvement in their symptoms. CyberKnife also provided an opportunity to successfully retreat 24 patients who had relapsed within two years from their first treatment.

For more information on CyberKnife treatment for meningiomas or trigeminal neuralgia, view our conditions treated page.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.